Abstract
In the last decades the epidermal growth factor receptor (EGFR), which is frequently expressed in a variety of epithelial tumors, has been a major target of molecular anticancer therapy.
Keywords: EGFR, Monoclonal antibody, Tyrosine kinase inhibitor, resistance
Current Cancer Therapy Reviews
Title: Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors
Volume: 3 Issue: 4
Author(s): Floriana Morgillo, Giampaolo Tortora and Fortunato Ciardiello
Affiliation:
Keywords: EGFR, Monoclonal antibody, Tyrosine kinase inhibitor, resistance
Abstract: In the last decades the epidermal growth factor receptor (EGFR), which is frequently expressed in a variety of epithelial tumors, has been a major target of molecular anticancer therapy.
Export Options
About this article
Cite this article as:
Morgillo Floriana, Tortora Giampaolo and Ciardiello Fortunato, Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors, Current Cancer Therapy Reviews 2007; 3 (4) . https://dx.doi.org/10.2174/157339407782496988
DOI https://dx.doi.org/10.2174/157339407782496988 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Repair Proteins as Molecular Targets for Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Interpreting the Mechanisms by which Integrins Promote the Differentiation of Mesenchymal Stem Cells and Integrin Application Prospects
Current Stem Cell Research & Therapy Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design FOXM1 and its Oncogenic Signaling in Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets ABC Transporters in the CNS – An Inventory
Current Pharmaceutical Biotechnology Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Current Drug Targets Therapeutic Exploitation of Apoptosis and Autophagy for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Epigenetic MicroRNA Regulation of Multiple Chromatin Functions: A Perspective in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Advancing the Therapeutic Efficacy of Bioactive Molecules by Delivery Vehicle Platforms
Current Medicinal Chemistry The Development of Future Research Strategies from Reviewing Antiemetic Trials for Chemotherapy Induced Emesis
Reviews on Recent Clinical Trials Addressing the Challenge: Current and Future Directions in Ovarian Cancer Therapy
Current Gene Therapy Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets Metabolic Fate of Endocannabinoids
Current Neuropharmacology Role of Isoprenoid Compounds on Angiogenic Regulation: Opportunities and Challenges
Current Medicinal Chemistry Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
Current Drug Targets Editorial [Hot topic: Current Formulations and Techniques of Drug/gene Delivery for Targeted Therapy and Tissue Engineering (Executive Editors: Chi-Hwa Wang and Sudhir H. Ranganath)]
Current Pharmaceutical Design Continuous Nanostructures for the Controlled Release of Drugs
Current Pharmaceutical Design Chemoinformatics in Multi-target Drug Discovery for Anti-cancer Therapy: In Silico Design of Potent and Versatile Anti-brain Tumor Agents
Anti-Cancer Agents in Medicinal Chemistry